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cAMP, reduced phosphorylation (activation) of ERK and Akt (protein kinases known to increase cyclin D
expression and activity, respectively), and reduced levels of cyclin D1 (cyclin that promotes cell-cycle pro-
gression in G1). Moreover, 2-chloroadenosine inhibited expression of S-phase kinase–associated protein-2
(Skp2; promotes proteolysis of p27Kip1) and upregulated levels of p27Kip1 (cell-cycle regulator that
impairs cyclin D function). 2-Chloroadenosine also inhibited signaling downstream of cyclin D, including
hyperphosphorylation of retinoblastoma protein and expression of cyclin A (S phase cyclin). Knockdown
of A2B receptors prevented the effects of 2-chloroadenosine on ERK1/2, Akt, Skp2, p27Kip1, cyclin D1,
cyclin A, and proliferation. Likewise, inhibition of adenylyl cyclase and protein kinase A abrogated 2-
chloroadenosine’s inhibitory effects on Skp2 and stimulatory effects on p27Kip1 and rescued HCASMCs
from 2-chloroadenosine–mediated inhibition. Knockdown of p27Kip1 also reversed the inhibitory effects of
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(20 ￿mol/L for 7 days) downregulated vascular expression of Skp2, upregulated vascular expression of
p27Kip1, and reduced neointima hyperplasia by 71% (P<0.05; neointimal thickness: control, 37 424±18
371 pixels; treated, 10 352±2824 pixels). In conclusion, the adenosine/A2B receptor/cAMP/protein ki-
nase A axis inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and
Skp2) that converge at cyclin D, a key G1 cyclin that controls cell-cycle progression.
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Abstract—The goal of this study was to determine whether and how adenosine affects the proliferation of human coronary 
artery smooth muscle cells (HCASMCs). In HCASMCs, 2-chloroadenosine (stable adenosine analogue), but not N6-
cyclopentyladenosine, CGS21680, or N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, inhibited HCASMC 
proliferation (A2B receptor profile). 2-Chloroadenosine increased cAMP, reduced phosphorylation (activation) of 
ERK and Akt (protein kinases known to increase cyclin D expression and activity, respectively), and reduced levels 
of cyclin D1 (cyclin that promotes cell-cycle progression in G1). Moreover, 2-chloroadenosine inhibited expression 
of S-phase kinase–associated protein-2 (Skp2; promotes proteolysis of p27Kip1) and upregulated levels of p27Kip1 (cell-
cycle regulator that impairs cyclin D function). 2-Chloroadenosine also inhibited signaling downstream of cyclin D, 
including hyperphosphorylation of retinoblastoma protein and expression of cyclin A (S phase cyclin). Knockdown 
of A2B receptors prevented the effects of 2-chloroadenosine on ERK1/2, Akt, Skp2, p27Kip1, cyclin D1, cyclin A, and 
proliferation. Likewise, inhibition of adenylyl cyclase and protein kinase A abrogated 2-chloroadenosine’s inhibitory 
effects on Skp2 and stimulatory effects on p27Kip1 and rescued HCASMCs from 2-chloroadenosine–mediated inhibition. 
Knockdown of p27Kip1 also reversed the inhibitory effects of 2-chloroadenosine on HCASMC proliferation. In vivo, 
peri-arterial (rat carotid artery) 2-chloroadenosine (20 μmol/L for 7 days) downregulated vascular expression of Skp2, 
upregulated vascular expression of p27Kip1, and reduced neointima hyperplasia by 71% (P<0.05; neointimal thickness: 
control, 37 424±18 371 pixels; treated, 10 352±2824 pixels). In conclusion, the adenosine/A2B receptor/cAMP/protein 
kinase A axis inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that 
converge at cyclin D, a key G1 cyclin that controls cell-cycle progression.  (Hypertension. 2015;66:1207-1219. DOI: 
10.1161/HYPERTENSIONAHA.115.05912.) • Online Data Supplement
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Excessive proliferation of some cell types (eg, vascular smooth muscle cells [VSMCs], glomerular mesangial 
cells [cells phenotypically similar to VSMCs], and cardiac 
fibroblasts) and deficient proliferation of other cell types (eg, 
vascular endothelial cells and renal epithelial cells) can trig-
ger hypertension-induced pathological vascular, cardiac, and 
renal remodeling, leading to cardiovascular and renal diseases.1 
Thus, endogenous factors that inhibit proliferation of VSMCs, 
glomerular mesangial cells, and cardiac fibroblasts and that 
stimulate the proliferation of vascular endothelial cells and 
renal epithelial cells may provide protection against cardio-
vascular and renal diseases. Adenosine seems to be one such 
factor. Adenosine potently inhibits the proliferation of rat renal 
preglomerular VSMCs,2,3 rat4–8 and human9 aortic VSMCs, 
rat3,10 and human11 glomerular mesangial cells, and rat cardiac 
fibroblasts12–16; yet, adenosine stimulates the proliferation of rat 
aortic,17 rat renal microvascular,18 and porcine coronary17 vas-
cular endothelial cells, as well as human18 renal epithelial cells. 
In addition, adenosine has several other desirable tissue-pro-
tecting actions, such as promoting neovascularization19–21 and 
preventing and reducing inflammation and hypoxia.22–27 Thus, 
adenosine per se, adenosine receptor agonists, or adenosine-
modulating drugs (ie, the broad class of adenosinergic drugs) 
may be useful for preventing and treating several cardiovascular 
Vascular Biology
1208  Hypertension  December 2015
and renal diseases induced by hypertension, particularly those 
associated with excessive proliferation of VSMCs. However, 
whether adenosine inhibits human coronary artery smooth mus-
cle cell (HCASMC) proliferation is unclear, and one objective 
of the current study was to determine the effects of adenosine 
on this critically important cell type.
Although adenosine is well known to inhibit prolifera-
tion of some types of VSMCs, the underlying mechanism by 
which adenosine inhibits mitogen-induced cell proliferation 
is unknown. There is increasing evidence that mitogens pro-
mote cell proliferation by engaging ERK1/2 and Akt signaling 
pathways that converge at cyclin D (Figure 1), a G1 phase 
cyclin with 3 isoforms (D1, D2, and D3, with D1 being the 
most widely expressed). ERK1/2 phosphorylates transcrip-
tion factors that increase the expression of cyclin D28, whereas 
Akt increases the activity of cyclin D via phosphorylating 
ezrin–radixin–moesin–binding phosphoprotein 50. In this 
regard, ezrin–radixin–moesin–binding phosphoprotein 50 
stabilizes S-phase kinase–associated protein-2 (Skp2) and 
optimizes its cellular location.29 Skp2 promotes the polyubiq-
uitination of p27Kip1 and thus accelerates p27Kip1 degradation,30 
thereby decreasing levels of p27Kip1. Normally, p27Kip1 binds 
to complexes of cyclins with their respective cyclin-depen-
dent kinases (Cdk), thus preventing cyclin–Cdk complexes 
from phosphorylating their substrates.31 Importantly, p27Kip1 
impairs the function of cyclin D–Cdk4/6 complexes31 that are 
primarily responsible for promoting cell-cycle progression 
in G1 phase of the cell cycle.32,33 Therefore, a reduction of 
p27Kip1 augments cyclin D activity. Cyclin D promotes, via 
activation of Cdk4/6, hyperphosphorylation of retinoblastoma 
protein (Rb), causing Rb to release the protein elongation 2 
factor.34 Elongation 2 factor then serves as a transcription fac-
tor to increase the expression of genes for G1/S and S phase 
cyclins,34 thus driving the cell cycle through S and G2 phases 
and finally mitosis and cytokinesis (Figure 1).
How could adenosine interfere with mitogen-induced cell 
proliferation? Accumulating evidence suggests that in some 
cell types, adenosine mediates antiproliferative effects via A2B 
receptors.7,9,35,36 Stimulation of A2B receptors activates adenylyl 
cyclase, resulting in increased cAMP production,37 and stud-
ies by Wu et al demonstrate that cAMP, via protein kinase A 
(PKA), may downregulate the expression of Skp2,38,39 which 
in turn increases the levels of p27Kip1. In addition, PKA can 
interfere with signaling cascades that phosphorylate (activate) 
ERK1/240,41 and Akt,42 thus providing additional mechanisms 
for inhibiting cyclin D signaling. Together, this information 
suggests the hypothesis shown in Figure 1 that adenosine 
could inhibit HCASMC proliferation by engaging the A2B 
receptor/adenylyl cyclase/cAMP/PKA pathway, which is fol-
lowed by PKA-mediated inhibition of multiple signaling path-
ways that converge at cyclin D. The net result is the reduced 
expression and function of cyclin D, which arrests cells in G1. 
Another goal of the present study was to test this hypothesis.
Methods
Materials
Adenosine, 2-chloroadenosine (stable adenosine analogue), and 
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; increases endogenous 
adenosine by inhibiting adenosine deaminase and thus reducing the 
metabolism of adenosine to inosine) were purchased from Sigma-
Aldrich (St. Louis, MO). N6-cyclopentyladenosine (CPA; selective 
A1 receptor agonist), CGS21680 (selective A2A receptor agonist), 
8-cyclopentyl-1,3-dipropylxanthine (DPCPX; selective A1 receptor 
antagonist), 5-iodotubercidin (IDO; increases endogenous adenos-
ine by inhibiting adenosine kinase and thus reducing the metabo-
lism of adenosine to 5′-AMP), 5′-N-ethylcarboxamidoadenosine 
(NECA; nonselective adenosine receptor agonist), 
5′-N-methylcarboxamidoadenosine (MECA; nonselective adenosine 
receptor agonist), 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-
purin-9-yl]-N-methyl-β-d-ribofuranuronamide (IB-MECA; selective 
A3 receptor agonist), SCH442416 (selective A2A receptor antagonist), 
MRS1754 (selective A2B receptor antagonist), and VUF5574 (selec-
tive A3 receptor antagonist) were purchased from Tocris (Minneapolis, 
MN). 3H-thymidine (specific activity, 11.8 Ci/mmol) was purchased 
from PerkinElmer NEN (Walthan, MA). All other reagents were of 
tissue culture or best grade available.
Cell Cultures
HCASMCs from 3 donors were procured from GIBCO (Life 
Technologies, CA) and LONZA (Walkersville, MD). The cells were 
precharacterized for smooth muscle cell–specific markers and for 
their compatible (<5% variation) growth response to fetal calf serum 
(FCS; 2.5%). Cells were cultured in M231 culture medium contain-
ing smooth muscle growth supplement (Life Technologies, CA) and 
under standard tissue culture conditions as described previously.43 
HCASMCs in third to fifth passage were used for the growth and 
molecular assays.
3H-Thymidine Incorporation
To assess DNA synthesis by HCASMCs, we used 3H-thymidine 
incorporation as described previously.43 HCASMCs grown to sub-
confluence and serum-starved for 24 hours were treated for 48 hours 
with 2.5% FCS in medium with or without test agents. Four hours 
before the termination of the experiment, cells were pulsed with 
3H-thymidine, and the incorporation of 3H-thymidine into the DNA 
was analyzed by measuring radioactivity in the acid-insoluble frac-
tion using a β-scintillation counter.
Cell Number
After serum starvation, cultures were treated with 2.5% FCS with or 
without test agents. After 4 days, cells were dislodged by trypsiniza-
tion and counted in a Coulter Counter.
Cell Cycle Analysis
HCASMCs at 60% confluence were serum-starved for 24 hours and 
then grown in 2.5% FCS for 3 days. Cells were stained with prop-
idium iodide, and DNA content was analyzed by flow cytometry.
Cell Migration Studies
2.5% FCS-induced HCASMC migration was assessed using the mod-
ified Boydens chamber and as previously described in detail by us.43
Assays for Intracellular Mechanisms
Changes in the phosphorylation state of signal transduction proteins 
and changes in the expression of cell cycle regulatory proteins were 
analyzed by Western blotting as previously described.44 Briefly, cells 
were grown and treated in 60 mm culture dishes and were washed 
once with PBS and then lysed in 70 μL of lysis buffer (Cell Signaling 
Technology, Beverly, MA). The samples were sonicated, and the 
protein concentration was measured using a BCA protein assay kit 
(Pierce, Rockford, IL). Proteins were denatured by boiling the sam-
ples at 95°C for 5 minutes. Equal amounts of protein (10–20 μg/lane) 
were diluted in 5× loading buffer (Fermentas, Hanover, MD) plus 0.1 
mol/L dithiothreitol and 2.5% 2-mercaptoethanol, and proteins were 
resolved using a 10% sodium dodecyl sulfate–polyacrylamide gel 
and then transferred to a nitrocellulose membrane. Subsequently, for 
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specific protein expression, the membranes were blocked in 5% non-
fat dry milk in PBS/0.2% Tween 20 (overnight at 4°C) and incubated 
with the primary antibody for specific times at room temperature or 
4°C (Table S1 in the online-only Data Supplement). Primary antibod-
ies (Table S1) were diluted in washing buffer (1% nonfat dry milk in 
PBS/0.2% Tween 20) and were specific for the proteins investigated 
and had cross-reactivity for both human and rat proteins. Following 
incubation with the primary antibodies, the membranes were incubated 
for 1 hour with the second antibody (goat anti-mouse IgG-peroxidase 
conjugated [Pierce 31430, diluted 1:25 000] or goat anti-rabbit IgG-
peroxidase conjugated [Pierce 31460, diluted 1:25 000]). Peroxidase 
activity was detected using ECL (Pierce), and the membranes were 
exposed to Hyperfilm ECL (Amersham, Dübendorf, CH).
A2B and p27 Silencing Studies
Smart pool on target plus siRNA kit from Dharmacon was used 
according to the instructions to silence CDKN1B (p27kip1) or 
ADORA2B (human A2B adenosine receptors) in HCASMCs. Control 
smart pool siRNA from Dharmacon was used as control.
cAMP Levels
Extracellular (supernatant) and intracellular (cellular fraction) 
cAMPs were pooled, and total cAMP levels were analyzed by high-
performance liquid chromatography using our previously described 
method.9
Carotid Artery Injury Studies
Balloon injury–induced neointima formation was assessed in ani-
mals (male Wistar–Kyoto rats; 350–400 g; Harlan, Fullinsdorf, 
Switzerland), as described previously.45,46 Briefly, animals were anes-
thetized with ketamine plus xylazine (intraperitoneal injection). To 
induce arterial injury, the left common carotid artery was exposed at 
the bifurcation, and a 2F Fogarty embolectomy catheter was inserted. 
The inflated balloon was pulled through the common carotid artery 3× 
to completely denude the endothelium, and the external carotid artery 
was permanently ligated. 2-Chlororadenosine (20 μmol/L) was added 
to 25% (wt/vol) pluronic gel solution (F127, BASF Corp, Parsipanny, 
NJ) and kept in nongelled form at 4°C. The neck muscles adjacent to 
the carotid artery were separated to expose the artery and to provide 
a space for the gel by lifting the artery slightly from the muscle with 
forceps. The liquid solution (100 μL) was then topically applied with 
an Eppendorf pipet on the exposed carotid artery. At 37°C, the solu-
tion rapidly gelled, and the vessel was thus covered by a translucent 
layer enveloping the treated area (≈1 cm length of artery). Because no 
muscles were cut, all tissues returned to their original position, and 
the carotid artery was covered again by muscle. The skin was subse-
quently sutured into place with 3 to 4 stiches of silk suture. After 7 
days, the animals were euthanized and perfusion-fixed for morpho-
metric analysis. To assess the impact of 2-chloroadenosine on prolif-
eration of intimal carotid artery VSMCs after balloon injury, animals 
(placebo n=7, treated n=7) receiving the vehicle or 2-chloroadenosine 
were euthanized and perfusion-fixed 7 days after balloon injury and 
sections immunostained for Ki67 to assess proliferating carotid artery 
VSMCs. The 7-day period was selected because it is well documented 
that the proliferative activity of carotid artery VSMCs peaks at day 7 
after injury.47,48 To assess whether 2-chloroadenosine affects expres-
sion of Skp2 and p27Kip1 in vivo, rats (placebo n=5 and treated n=5) 
were euthanized on day 8 and the carotid arteries snap-frozen in liquid 
nitrogen. Subsequently, segments from placebo or 2-chloroadenosine–
treated animals were homogenized and lysed, and proteins of interest 
were analyzed using Western blotting.
Statistics
Treatment effects on cross-sectional areas were analyzed by using 
analysis of variance or the nonparametric Kruskal–Wallis test. 
Expression and growth data were analyzed using analysis of vari-
ance, and statistical significance (P<0.05) was calculated using 
Fisher’s least significant difference test. All growth experiments were 
performed in triplicates or quadruplicates using 3 separate HCASMC 
cultures. For Western blotting experiments, each treatment was con-
ducted in triplicate or quadruplicates and with 3 separate HCASMC 
cultures. The densitometeric analysis of protein expression is pre-
sented as a ratio against the appropriate control (phosphorylated 
ERK1/2 to ERK1/2; phosphorylated Akt to Akt; cyclin D1 to β-actin; 
cyclin A to β-actin; p27Kip1 to β-actin; Skp2 to β-actin).
Results
Because the expression profile of adenosine receptor subtypes 
may determine the overall pharmacology of adenosine, we 
first probed for the presence of adenosine receptor subtypes 
in the HCASMCs used in the present study. cDNA size frac-
tionation showed strong expression of mRNA for A1 and A2B 
receptors, but only weak mRNA expression for A2A and A3 
receptors (Figure 2A). Likewise, Western blotting detected 
strong bands for A1 and A2B receptors, a faint band for A2A 
Figure 1. Signaling schematic depicting our hypothesis of how 
adenosine regulates human coronary artery smooth muscle cell 
cell-cycle progression. Extracellular mitogens activate classical 
signal transduction pathways that ultimately phosphorylate (and 
thus activate) ERK1/2 and Akt. ERK1/2 is well known to increase 
expression of cyclin D (G1 phase cyclin). Phosphorylated Akt 
activates a signal transduction pathway that stabilizes S-phase 
kinase–associated protein-2 (Skp2), which is the F-box protein 
of SCFSkp2 ubiquitin ligase that polyubiquitinates p27Kip1 and 
thus accelerates the degradation of p27Kip1. Removal of p27Kip1 
deinhibits cyclin D activity. Cyclin D activates cyclin-dependent 
kinases 4 and 6 to hyper-phosphorylate retinoblastoma 
protein (Rb), thus releasing the transcription factor elongation 
2 factor (E2F) and allowing increased expression of G1/S and 
S phase cyclins. G1/S and S phase cyclins then drive the cell 
cycle forward to complete mitogenesis and cytokinesis (cell 
proliferation). Adenosine stimulates A2B receptors that are 
positively coupled to adenylyl cyclase, which increases the 
formation cAMP and activates protein kinase A. Protein kinase 
A decreases expression of Skp2 and inhibits phosphorylation of 
Akt, resulting in increased levels of p27Kip1 which reduce cyclin 
D activity. Protein kinase A also inhibits phosphorylation of 
ERK1/2, which reduces cyclin D expression. This protein kinase 
A (PKA)–induced signaling converges at cyclin D. This results in 
inhibition of Rb hyperphosphorylation, and hypophosphorylated 
Rb can now bind E2F and prevent this transcription factor from 
increasing the expression of G1/S and S phase cyclins.
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receptors, and no signal for A3 receptors (Figure 2A). These 
findings suggest that A1 or A2B receptors would likely domi-
nate the pharmacology of adenosine in these HCASMCs.
Treatment of HCASMCs with 2-chloroadenosine (stable 
adenosine analogue) concentration-dependently attenuated 
DNA synthesis (Figure 2B). Using various pharmacological 
agents (adenosine receptor subtype selective and nonselec-
tive agonists and antagonists), we further assessed the role 
of all adenosine receptor subtypes (A1, A2A, A2B, and A3) 
in mediating the anti-mitogenic effects in HCASMCs. The 
highest (1 μmol/L) concentrations of CPA (A1 receptor–
selective agonist), CGS21680 (A2A receptor–selective ago-
nist), and IB-MECA (A3 receptor–selective agonist) failed to 
inhibit DNA synthesis (Figure 2B). MECA was slightly more 
potent than NECA (both are nonselective adenosine recep-
tor agonists; Figure 2B). MRS1754 (A2B receptor–selective 
antagonist), but not DPCPX (A1 receptor–selective antago-
nist), SCH442416 (A2A receptor–selective antagonist), or 
VUF5574 (A3 receptor–selective antagonist), blocked the 
Figure 2. Adenosine A2B receptor mediated inhibition of human 
coronary artery smooth muscle cell growth. A, Representative 
northern blots (upper) and western blots (lower) showing 
the presence of A1 and A2B receptors, with low expression 
of A2A receptors and minimal expression of A3 receptors. B, 
Concentration–response relationships for the inhibition of 
3H-thymidine incorporation (DNA synthesis) by 2-chloroadenosine 
(Cl-Ad), 5′-N-methylcarboxamidoadenosine (MECA), 1-deoxy-1-
[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-d-
ribofuranuronamide (IB-MECA), 5′-N-ethylcarboxamidoadenosine 
(NECA), N6-cyclopentyladenosine (CPA), and CGS21680 (CGS). 
C, The effects of Cl-Ad (1 μmol/L) on DNA synthesis in the 
presence and absence of 8-cyclopentyl-1,3-dipropylxanthine 
(DPCPX; selective A1 antagonist, 100 nmol/L); SCH442416 (SCH; 
selective A2A antagonist, 100 nmol/L); VUF5574 (VUF; selective 
A3 antagonist, 100 nmol/L); and MRS1754 (MRS; selective A2B 
antagonist, 100 nmol/L). D, The inhibitory effects of Cl-Ad (100 
nmol/L) on cell-cycle distribution. *P<0.05 vs no treatment; 
§P<0.05 significant reversal of Cl-Ad effects. Values represent 
mean±SEM from 3 separate experiments, each conducted in 
triplicates or quadruplicates.
Figure 3. A, Bar graphs show the effects of 2-chloroadenosine 
(Cl-Ad; 1 μmol/L) and 5′-N-methylcarboxamidoadenosine 
(MECA; 1 μmol/L) on cell number in human coronary artery 
smooth muscle cells (HCASMCs). The inhibitory effects of Cl-Ad 
were reversed by MRS1754 (MRS; A2B receptor antagonist), but 
not by SCH442416 (SCH; A2A receptor antagonist), 8-cyclopentyl-
1,3-dipropylxanthine (DPCPX; A1 antagonist), or VUF5574 (VUF; 
A3 antagonist). Similar to Cl-Ad, the effects of MECA were 
blocked by MRS1754. *P<0.05 vs control; §significant reversal 
of the inhibitory effects. B, Bar graph demonstrates the effects 
of Cl-Ad (1 μmol/L) and MECA (1 μmol/L) on cell migration in 
HCASMCs. The inhibitory effects of Cl-Ad were mimicked by 
MECA, but not by N6-cyclopentyladenosine (CPA; A1 agonist), 
CGS21680 (CGS; A2A agonist), or 1-deoxy-1-[6-[[(3-iodophenyl)
methyl]amino]-9H-purin-9-yl]-N-methyl-β-d-ribofuranuronamide 
(IB-MECA; IB-M: A3 adenosine receptor agonist). Moreover, the 
effects of Cl-Ad and MECA were reversed by MRS1754 (MRS; 
A2B receptor antagonist). *P<0.05 vs control; §significant reversal 
of the inhibitory effects. C, Effects of erythro-9-(2-hydroxy-3-
nonyl)adenine (EHNA; 5 μmol/L; adenosine deaminase inhibitor) 
and 5-iodotubercidin (IDO; 0.1 μmol/L; adenosine kinase 
inhibitor) on cell number in HCASMCs. The inhibitory effects were 
significantly enhanced when the adenosine catabolism inhibitors 
EHNA+IDO were combined. Moreover, the effects of EHNA+IDO 
were reversed by MRS1754 (MRS; A2B receptor antagonist), 
but not by SCH442416 (SCH; A2A receptor antagonist), DPCPX 
(A1 antagonist), or VUF5574 (VUF; A3 antagonist), suggesting 
that endogenous adenosine inhibits HCASMC growth via 
A2B receptors. *P<0.05 vs control; §significant reversal of the 
inhibitory effects. Values represent mean±SEM from 3 separate 
experiments, each conducted in triplicates or quadruplicates.
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effects of 2-chloroadenosine on DNA synthesis (all antago-
nists at 100 nmol/L; Figure 2C). Moreover, the inhibitory 
effects of 2-chloroadenosine on cell number were reversed 
by MRS1754, but not by DPCPX, SCH442416, or VUF5574 
(Figure 3A). Similar to 2-chloroadenosine, the inhibi-
tory effects of MECA on cell number were antagonized by 
MRS1754 (Figure 3A). Treatment with 2-chloroadenosine 
and MECA, but not CPA, CGS21680, or IB-MECA, inhibited 
HCASMC migration, and the inhibitory effects of 2-chloro-
adenosine and MECA on cell migration were blocked by 
MRS1754 (Figure 3B). EHNA (blocks adenosine deaminase) 
and IDO (blocks adenosine kinase), administered separately, 
inhibited cell proliferation, and these effects were enhanced 
in cells treated with EHNA plus IDO (Figure 3C). MRS1754, 
but not DPCPX, SCH442416, or VUF5574, abrogated the 
inhibitory effects of EHNA plus IDO on cell proliferation 
(Figure 3C, right panel). Cell cycle distribution experiments 
using flow cytometry demonstrated that 2-chloroadenosine 
increased the percentage of cells in G0/G1 while reducing the 
percentage of cells in S phase and G2/M phase (Figure 2D). 
Trypan blue exclusion tests demonstrated that none of the 
aforementioned treatments altered cell viability. These find-
ings indicate that in HCASMCs, A2B receptors dominate the 
pharmacology of adenosine, leading to inhibition of cell pro-
liferation, DNA synthesis, and cell migration and arrest of 
cells in the G0/G1 phase of the cell cycle.
Treatment of HCASMCs with 2-chloroadenosine inhib-
ited hyperphosphorylation of Rb and phosphorylation of 
ERK1/2 and Akt (Figure 4). Moreover, treatment with 2-chlo-
roadenosine decreased levels of Skp2 (F-box protein of 
SCFSkp2 ubiquitin ligase responsible for polyubiquitination of 
and subsequent proteolysis of p27Kip1) and upregulated levels 
of p27Kip1 (p27Kip1 inhibits cell cycle progression by block-
ing function of cyclins). These effects were accompanied by 
inhibition of cyclin A and cyclin D1 expression (Figure 4). 
The modulatory effects of 2-chloroadenosine on signal trans-
duction proteins were mimicked by MECA, but not by CPA, 
CGS21680, or IB-MECA (Figure 4). The modulatory effects 
of 2-chloroadenosine and MECA on signal transduction path-
ways were blocked by MRS1754 (Figure 4), implying a role 
for A2B receptors in mediating the inhibitory effects of adenos-
ine on cell cycle progression in HCASMCs.
Western blotting confirmed that treatment with siRNA 
silenced the expression of A2B receptors (Figure 5A). At the 
functional level, 2-chloroadenosine increased cAMP pro-
duction in control cells and cells treated with negative-con-
trol siRNA, but not in cells treated with A2B receptor siRNA 
(Figure 5A). 2-Chloroadenosine inhibited DNA synthesis in 
HCASMCs treated with negative-control siRNA but not in 
cells treated with A2B siRNA (Figure 5B). Also the inhibitory 
effects of MECA, NECA, and EHNA+IDO were blocked by 
A2B siRNA (Figure 5B). Downregulation of A2B receptors by 
siRNA did not abrogate the inhibitory effects of 8-bromo-
cAMP on DNA synthesis (Figure 5B). These results further 
support the conclusion that A2B receptors mediate the anti-
mitogenic effects of adenosine.
In HCASMCs in which A2B receptors were silenced, treat-
ment with 2-chloroadenosine failed to abrogate phosphoryla-
tion of key signal transduction proteins (pRb, ERK1/2, and Akt) 
associated with cell proliferation (Figure 6). The inhibitory 
effects of 2-chloroadenosine on cell cycle regulatory proteins 
cyclin A and cyclin D1 were also abrogated in HCASMCs with 
silenced A2B receptors. Additionally, the inhibitory effects of 
2-chloroadenosine on Skp2 and stimulatory effects on p27Kip1 
were lost in HCASMCs lacking A2B receptors (Figure 6).
cAMP may inhibit HCASMC proliferation via Skp2 
downregulation and p27Kip1 upregulation.38 Because 2-chlo-
roadenosine–stimulated cAMP production was inhibited 
in HCASMCs with silenced A2B receptors, we further elu-
cidated the role of this pathway in mediating the inhibitory 
effects of 2-chloroadenosine on cell proliferation. Treatment 
of HCASMCs with 2-chloroadenosine concentration–depend-
ently decreased Skp2 and increased p27Kip1 expression (Figure 
7A). The stimulatory effects of 2-chloroadenosine on p27Kip1 
expression in HCASMCs was abolished in cells in which 
adenosine A2B receptors were silenced with siRNA (Figure 
7B). Moreover, the inhibitory effects of 2-chloroadenosine on 
DNA synthesis were abrogated in HCASMCs in which ade-
nosine A2B receptors were silenced (Figure 7B). The obser-
vations that the stimulatory effects of 2-chloroadenosine on 
p27Kip1 and inhibitory effects on DNA synthesis are abolished 
in HCASMCs lacking adenosine A2B receptors suggest a role 
Figure 4. Western blots show effects of 0.5 μmol/L of 
2-chloroadenosine (Cl-Ad), 5′-N-methylcarboxamidoadenosine 
(MECA), N6-cyclopentyladenosine (CPA), CGS21680 (CGS), 
1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-
yl]-N-methyl-β-d-ribofuranuronamide (IB-MECA; IB-M), 
Cl-Ad+MRS1754 (MRS; 100 nmol/L), or MECA+MRS1754 
on levels of hyperphosphorylated retinoblastoma protein 
(pRb), phosphorylated ERK1/2 (ERK1/2-P), total ERK1/2, 
phosphorylated Akt (Akt-P), total Akt, cyclin D1, cyclin A, 
p27Kip1 (p27), and S-phase kinase–associated protein-2 (Skp2) 
expression in human coronary artery smooth muscle cells 
(HCASMCs). Sub-confluent monolayers of HCASMCs growth 
arrested for 36 hours in 0.4% BSA were treated and stimulated 
with 2.5% fetal calf serum (FCS) for 48 hours. Cell lysates were 
subsequently analyzed by western blotting. The densitometric 
analysis of all the protein expression is presented as a ratio 
against the appropriate control (phosphorylated ERK1/2 to 
ERK1/2; phosphorylated Akt to Akt; cyclin D1 to β-actin; cyclin 
A to β-actin; p27Kip1 to β-actin; Skp2 to β-actin). *P<0.05 versus 
control; §significant reversal of the inhibitory effects. Values 
represent mean±SEM from 3 separate experiments, each 
conducted in triplicates or quadruplicates.
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for p27Kip1 in A2B receptor-mediated regulation of HCASMC 
proliferation.
Next, we tested whether adenylyl cyclase and PKA medi-
ate the effects of 2-chloroadenosine on p27Kip1 and HCASMC 
growth via A2B receptors. 2-Chloroadenosine inhibited Skp2 
and upregulated p27Kip1 in the absence (Figure 8A) but not in 
the presence of the adenylyl cyclase inhibitor myristoylated 
trifluoroacetate or the PKA inhibitor 2′,5′-dideoxyadenosine 
(Figure 8A). Also, the inhibitory effects of 2-chloroadenosine 
on HCASMC DNA synthesis were blocked by PKA and ade-
nylyl cyclase inhibitors (Figure 8A). To further confirm the 
link between cAMP and p27Kip1 in mediating the inhibitory 
effects of 2-chloroadenosine via A2B receptors, we assessed 
the effects of 2-chloroadenosine on DNA synthesis in 
HCASMCs, where p27Kip1 expression was silenced. Treatment 
of HCASMCs with p27Kip1 siRNA silenced p27Kip1 expres-
sion compared with cells treated with negative-control siRNA 
(Figure 8B). 2-Chloroadenosine inhibited DNA synthesis in 
HCASMCs treated with negative-control siRNA, but not in 
HCASMCs where p27Kip1 was silenced. Similar to 2-chloro-
adenosine, MECA and 8-bromo-cAMP inhibited DNA syn-
thesis in HCASMCs treated with negative-control siRNA, but 
not in cells in which p27Kip1 was silenced (Figure 8C).
In serum-starved HCASMCs, silencing of A2B receptors 
with siRNA resulted in a significant increase in DNA synthe-
sis, and these effects were further enhanced by the A1 ade-
nosine receptor agonist CPA (Figure 9). Pretreatment with 
DPCPX, an A1 receptor antagonist, blocked the stimulatory 
effect of A2B silencing under basal conditions and in response 
to CPA. These finding indicate that in the absence of A2B 
receptors, endogenous adenosine induces HCASMC growth 
via A1 receptors.
Morphometeric analysis of carotid arteries showed sig-
nificant intimal thickening after balloon injury, and this was 
significantly inhibited in rats receiving 2-chloroadenosine 
for 7 days. As shown in Figure 10A, compared with the 
placebo group (n=7; intima 37 424±18 371 pixels), the neo-
intima formation was reduced by 71% in rats receiving peri-
arterial 2-chloroadenosine (n=7; 10 352±2824; P<0.05 versus 
Figure 6. Inhibitory effects of 0.5 μmol/L of 2-chloroadenosine 
(Cl-Ad) on levels of hyper-phosphorylated (Hyper-P) and 
hypo-phosphorylated (Hypo-P) pRb, phosphorylated ERK1/2 
(ERK1/2-P), total ERK1/2, phosphorylated Akt (Akt-P), total Akt, 
cyclin A, cyclin D1, S-phase kinase–associated protein-2 (Skp2), 
and p27Kip1 (p27) expression in human coronary artery smooth 
muscle cells (HCASMCs) in the absence (−siRNA) and presence 
(+siRNA) of A2B receptor siRNA. Sub-confluent monolayers of 
HCASMCs were growth-arrested for 36 hours in 0.4% BSA and 
were treated and stimulated with 2.5% fetal calf serum (FCS) for 
48 hours. Cell lysates were subsequently analyzed by Western 
blotting. The modulatory effects of Cl-Ad on the signaling and 
cell cycle–regulating proteins were lost in the absence of A2B 
receptors. Bar graphs depict the optical density (OD) or OD 
ratio (phosphorylated ERK1/2 to ERK1/2; phosphorylated Akt to 
Akt; cyclin D1 to β-actin; cyclin A to β-actin; p27Kip1 to β-actin; 
Skp2 to β-actin) for the Western blots. *P<0.05 versus control. 
Values represent mean±SEM from 3 separate experiments, each 
conducted in triplicates.
Figure 5. A (Top), Western blot depicting the downregulation 
of the expression of A2B receptors in human coronary artery 
smooth muscle cells (HCASMCs) by siRNA against A2B receptors. 
No treatment with siRNA (Con); treated with negative-control 
siRNA (si-Con); treated with siRNA against A2B receptor (siRNA). 
Bar graph for the western blot represents change in optical 
density ratio of A2B to β-actin. (Bottom), Depicts the effects 
of siRNA against A2B receptors on the stimulatory effects 
of 2-chloroadenosine (Cl-Ad; 1 μmol/L) on cAMP levels in 
HCASMCs. No treatment with siRNA (Control); treated with 
negative-control siRNA (siControl); treated with siRNA against 
A2B receptor (siRNA). *P<0.05 vs no Cl-Ad. B, Inhibitory effects 
of Cl-Ad, 5′-N-methylcarboxamidoadenosine (MECA), 5′-N-
ethylcarboxamidoadenosine (NECA), N6-cyclopentyladenosine 
(CPA), 8-bromo-cAMP (cAMP), and erythro-9-(2-hydroxy-3-
nonyl)adenine (EHNA; 10 μmol/L) plus 5-iodotubercidin (IDO; 
0.1 μmol/L) on DNA synthesis in the absence and presence of 
A2B receptor siRNA in HCASMCs. No treatment with agonists 
(Control); treated with negative-control siRNA (si-Control); 
treated with siRNA against A2B receptor (A2B-siRNA)]. *P<0.05 
vs no agonist; §significant reversal of the inhibitory effects. 
Values represent mean±SEM from 3 separate experiments, each 
conducted in triplicates.
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placebo). The media and lumen areas did not significantly 
differ between the placebo and the 2-chloroadenosine-treated 
group (Table S2); however, the intimal/medial ratio was sig-
nificantly reduced in animals receiving 2-chloroadenosine 
(Table S2). In carotid arteries obtained from animals receiv-
ing placebo, Ki67-positive cells (indicating proliferating of 
VSMCs) were observed (Figure 10B). As compared with the 
placebo group, a significant decrease in Ki67-positive VSMCs 
was observed in arteries obtained from animals treated with 
2-chloroadenosine (Figure 10B). Treatment with 2-chloro-
adenosine was not associated with any toxic adverse effects. In 
this regard, the WBC count, RBC count, and hematocrit did not 
differ between placebo and 2-chloroadenosine-treated groups 
(Table S2). To assess whether Skp2 and p27Kip1 are involved in 
mediating the inhibitory effects of 2-chloroadenosine on inti-
mal formation after balloon injury, we analyzed their levels 
in carotid lysates. As shown in Figure 10C, compared with 
placebo (n=5), treatment with 2-chloroadenosine (n=5) down-
regulated the expression of Skp2 and upregulated the expres-
sion of p27Kip1.
In the studies described earlier, we used 2-chloro-
adenosine rather than adenosine because adenosine is rapidly 
metabolized (necessitating frequent treatments), whereas 
2-chloroadenosine is resistant to metabolism (allowing 
once daily treatments). To make sure that adenosine per se 
qualitatively has the same effects as 2-chloroadenosine, we 
assessed the effects of adenosine on HCASMC proliferation. 
As shown in Figure 11A, adenosine inhibited DNA synthe-
sis in a concentration-dependent manner. As expected, when 
cells were treated daily, adenosine was ≈10-fold less potent 
than 2-chloroadenosine in inhibiting HCASMC proliferation. 
Moreover, similar to 2-chloroadenosine, the inhibitory effects 
of adenosine were blocked by the A2B receptor antagonist 
MRS1754 (Figure 11B). To assess whether decreased potency 
of adenosine is caused by its catabolism by adenosine deami-
nase and adenosine kinase, we assessed the growth inhibitory 
effects of adenosine in the presence and absence of adenosine 
deaminase and adenosine kinase inhibitors EHNA and IDO. 
The inhibitory effects of adenosine on cell number were sig-
nificantly enhanced by EHNA+IDO (Figure 11B), and this 
effect was reversed by the A2B receptor antagonist MRS1754, 
suggesting that adenosine catabolism is responsible for its 
reduced inhibitory potency in HCASMCs. To assess whether 
adenosine, like 2-chloroadenosine, inhibits HCASMC growth 
via upregulation of p27Kip1 and downregulation of Skp2, we 
assessed adenosine’s effect on the expression of both p27Kip1 
and Skp2. As shown in Figure 11C, treatment of HCASMCs 
with adenosine upregulated p27Kip1 and downregulated Skp2 
expression. Taken together, these observations suggest that 
adenosine, although less potent than 2-chloroadenosine, 
inhibits HCASMC growth via similar mechanisms.
Discussion
Our experiments demonstrate that exogenous, as well as 
endogenous, adenosine inhibits mitogen-induced proliferation 
and migration of HCASMCs. In support of this conclusion, 
we observe that treatment of HCASMCs with a metaboli-
cally stable adenosine analog (2-chloroadenosine) or with 
agents that increase endogenous adenosine (EHNA plus IDO) 
inhibits HCASMC DNA synthesis, cell proliferation, and cell 
migration.
Our results also support the conclusion that adenosine 
inhibits proliferation of HCASMCs via activation of A2B recep-
tors. CPA, CGS21680, and IB-MECA are selective A1 recep-
tor, A2A receptor, and A3 receptor agonists, respectively; and 
DPCPX, SCH442416, and VUF5574 are selective A1 recep-
tor, A2A receptor, and A3 receptor antagonists, respectively. 
Because neither low concentrations of CPA, CGS21680, nor 
IB-MECA inhibit HCASMC proliferation and because nei-
ther DPCPX, SCH442416, nor VUF5574 blocks the inhibi-
tory effects of 2-chloroadenosine on HCASMC proliferation, 
it is highly unlikely that A1, A2A, or A3 receptors mediate the 
anti-mitogenic effects of adenosine on HCASMCs. Because 
there are only 4 known adenosine receptor subtypes and 
3 of the 4 are ruled out, by the process of elimination, the 
A2B receptor most likely is the receptor mediating the effects 
of adenosine on HCASMC growth. MECA and NECA are 
adenosine receptor agonists that activate multiple adenosine 
receptor subtypes, including A2B receptors, and MRS1754 is 
an adenosine receptor antagonist that blocks selectively A2B 
receptors. The fact that MECA and NECA mimic the effects 
Figure 7. A, Concentration-dependent modulatory effects 
of 2-chloroadenosine (Cl-Ad) on S-phase kinase–associated 
protein-2 (Skp2) and p27Kip1 (p27) levels in human coronary 
artery smooth muscle cells (HCASMCs). Treatment of HCASMCs 
with Cl-Ad for 48 hours downregulated the expression of Skp2 
and upregulated the expression of p27Kip1 (p27). B, Effects of 
Cl-Ad on p27Kip1 expression and DNA synthesis in HCASMCs 
with downregulated A2B receptors. Compared with HCASMCs 
treated with negative-control siRNA (-Si RNA or siControl), Cl-Ad 
–induced expression of p27Kip1 and inhibition of DNA synthesis 
was abrogated in HCASMCs treated with siRNA against A2B 
receptors (+SiRNA or A2B-siRNA). The optical density (OD) 
ratio in the bar graphs represents ratio of Skp2, p27Kip1, or A2B 
receptor to β-actin. Values represent mean±SEM from 3 separate 
experiments, each conducted in triplicates.
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of 2-chloroadenosine on HCASMC proliferation and the fact 
that MRS1754 attenuates the inhibitory effects of 2-chloro-
adenosine and MECA on HCASMC proliferation corrobo-
rate the conclusion that A2B receptors mediate the inhibitory 
effects of adenosine on HCASMC proliferation. This conclu-
sion is confirmed by our findings that the inhibitory effects of 
MECA, NECA, and 2-chloroadenosne on HCASMC prolif-
eration are blocked by siRNA against A2B receptors.
Multiple pro-mitogenic pathways—including ERK1/2 
and Akt—are involved in triggering the proliferative response 
of mitogens generated at sites of vascular dysfunction or 
injury. These early signaling pathways trigger proliferation of 
HCASMCs by upregulating cell cycle regulatory proteins—
such as cyclin D and cyclin A—that promote cell-cycle 
progress or by downregulating regulatory proteins—such as 
p27Kip1—that retard cell-cycle progression.45,47 The present 
study shows that treatment with 2-chloroadenosine or MECA, 
but not CPA, CGS21680, or IB-MECA, inhibits phosphory-
lation of ERK1/2 and Akt, decreases expression of Skp2, 
increases levels of p27Kip1, decreases expression of cyclin 
D1, inhibits hyper-phosphorylation of Rb, and downregulates 
expression of cyclin A. These results are entirely consistent 
with the proposed mechanism of adenosine’s antiproliferative 
action outlined in Figure 1. The role of A2B receptors in modu-
lating these key signaling mechanisms to negatively influence 
cell proliferation is further supported by our observation that 
the effects of 2-chloroadenosine and MECA on these signaling 
pathways are blocked by the A2B receptor antagonist MRS1754 
and by silencing of A2B receptors using siRNA. Therefore, 
these findings corroborate the concept that A2B receptor acti-
vation causes a realignment of signaling pathways to inhibit 
HCASMC proliferation by the mechanism shown in Figure 1.
Skp2 is an F-box protein of SCFSkp2 ubiquitin ligase and 
therefore promotes polyubiquitination of and subsequent 
proteolysis of p27Kip1.30,49 Because p27Kip1 binds to and inhib-
its the function of cyclin–Cdk complexes (such as cyclin D/
Cdk4/6), an increase in p27Kip1 levels would inhibit the func-
tion of cyclin D. Thus, we hypothesize that via A2B receptors, 
adenosine inhibits HCASMC proliferation in part by down-
regulating Skp2 and upregulating p27Kip1. Consistent with this 
Figure 8. A, Protein kinase A (PKA) and adenylyl cyclase (AC) pathways mediate the inhibitory effects of 2-chloroadenosine (Cl-Ad) on 
human coronary artery smooth muscle cell (HCASMC) proliferation via modulation of S-phase kinase–associated protein-2 (Skp2) and 
p27Kip1. Western blots show Skp2 and p27Kip1 expression in HCASMCs treated with Cl-Ad (0.5 μmol/L) in presence or absence of a protein 
kinase A inhibitor (myristoylated trifluoroacetate, frag 14–22; 10 μmol/L; PKA-I) or adenylyl cycliase inhibitor (2′,5′ dideoxyadenosine; 
1 μmol/L; AC-I) for 48 hours. Treatment of HCASMCs with Cl-Ad upregulated p27Kip1 and downregulated Skp2, and these effects were 
abrogated by both PKA-I and AC-I. Both PKA-I and AC-I also reversed the inhibitory effects of Cl-Ad on DNA synthesis in HCASMCs. 
*P<0.05, no Cl-Ad (−Cl-Ad) vs Cl-Ad (+Cl-Ad); §significant reversal of the inhibitory effects. B, Role of p27Kip1 in mediating the growth 
inhibitory actions of Cl-Ad in HCASMCs. In contrast to HCASMCs treated with control siRNA (-Si RNA or Si-Con), treatment of 
HCASMCs with p27Kip1 siRNA (+Si RNA or p27-siRNA) blocked Cl-Ad –induced expression of p27Kip1 (Western blots). The inhibitory 
effects of Cl-Ad on DNA synthesis were abrogated in HCASMCs with silenced p27Kip1. C, Similar to Cl-Ad, the inhibitory effects of 
5′-N-methylcarboxamidoadenosine (MECA) and 8-bromo-cAMP (Br-cAMP) were abrogated in HCASMCs treated with p27Kip1 siRNA 
(p27-siRNA) but not in HCASMCs treated with control siRNA (si-Control). *P<0.05 vs control; §significant reversal of the inhibitory effects. 
Values represent mean±SEM from 3 separate experiments, each conducted in triplicates. The optical density (OD) ratio in the bar graphs 
represents Skp2 or p27Kip1 to β-actin ratio.
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notion, our results show that treatment with 2-chloroadenosine 
reduces Skp2 expression, and this is accompanied by a simul-
taneous increase in p27Kip1 levels. Using pharmacological ago-
nists and antagonists and molecular silencing of A2B receptors, 
we demonstrate that the modulatory effects of adenosine on 
Skp2 and p27Kip1 are A2B receptor–mediated. Consistent with 
our contention that the anti-mitogenic effects of adenosine are 
mediated in part by inhibiting the proteolytic actions of Skp2 
on p27Kip1, we also observe that via A2B receptors (pharmaco-
logical and molecular approaches), 2-chloroadenosine as well 
as MECA inhibit cyclin D–dependent downstream signaling, 
that is, hyper-phosphorylation of Rb and expression of cyclin 
A (Figure 1). These modulatory actions of 2-chloroadenosine 
on ERK1/2, Akt, Skp2, p27Kip1, cyclin D, Rb, and cyclin A are 
also consistent with our observation that 2-chloroadenosine 
increases the percentage of cells in the G0/G1 phase of the cell 
cycle, although decreasing the percentage of cells in the S and 
G2/M phases of the cell cycle.
Our studies are consistent with the concept that the proxi-
mal signaling mechanism by which A2B receptors inhibit 
proliferation involves the adenylyl cyclase/cAMP/PKA axis 
(Figure 1). A2B receptors induce cAMP formation via activa-
tion of adenylyl cyclase.50 Therefore, cAMP may be involved 
in mediating the effects of 2-chloroadenosine on ERK1/2, Akt, 
and Skp2. Our finding that the inhibitory effects of 2-chloro-
adenosine on HCASMC proliferation are significantly abro-
gated by inhibition of adenylyl cyclase and PKA are consistent 
with the hypothesis that A2B-mediated cAMP production par-
ticipates in the anti-mitogenic effects of 2-chloroadenosine. 
We also observe that in HCASMCs with siRNA-silenced 
A2B receptors, 2-chloroadenosine–induced cAMP produc-
tion is abrogated and the anti-mitogenic effects of 2-chloro-
adenosine and MECA, but not 8-bromo-cAMP, are prevented. 
Together, these data suggest that the antiproliferative effects 
of 2-chloroadenosine are mediated by cAMP produced via A2B 
receptor activation. The involvement of cAMP in mediating 
the effects of 2-chloroadenosine on Skp2 and p27Kip1 via A2B 
receptors is supported by the fact that the inhibitory effects of 
2-chloroadenosine on Skp2 expression and the concomitant 
stimulatory effects of 2-chloroadenosine on p27Kip1 levels are 
attenuated by inhibition of adenylyl cyclase, PKA, and A2B 
receptors and abrogated in HCASMCs lacking A2B receptors. 
Taken together and as shown in Figure 1, our findings suggest 
that the anti-mitogenic effects of adenosine are mediated via 
Figure 9. Bar graphs depict the balanced regulation of human 
coronary artery smooth muscle cell (HCASMC) proliferation by 
A2B and A1 adenosine receptors. In serum-starved HCASMCs, 
silencing of A2B receptors with siRNA (+A2B-siRNA) resulted 
in a significant increase in DNA synthesis, and these effects 
were further enhanced by the A1 adenosine receptor agonist 
N6-cyclopentyladenosine (CPA; 100 nmol/L). Pretreatment with 
8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 10 nmol/L), an 
A1 receptor antagonist, blocked the stimulatory effect of A2B 
silencing under basal conditions and in response to CPA. These 
finding indicate that downregulation of A2B receptors increases 
DNA synthesis under basal conditions, suggesting that in the 
absence of A2B receptors, endogenous adenosine induces 
HCASMC growth via A1 receptors. This is further supported 
by the observation that CPA further stimulated DNA synthesis, 
and this effect was blocked by DPCPX. *P<0.05, vs no siRNA 
(–siRNA) and vs control siRNA (+si-Control) in medium with 
0.4% BSA; §significant reversal of the proliferative effects of A2B 
siRNA with or without CPA. Values represent mean±SEM from 3 
separate experiments using separate cultures, each conducted 
in triplicates.
Figure 10. A, Inhibitory effects of 2-chloroadenosine (Cl-
Ad) on intimal thickening after balloon injury. Image shows 
representative photomicrographs (40× magnification) of the 
cross sections of rat carotid arteries 7 days after balloon injury. 
Compared with rats receiving vehicle (placebo), intimal thickening 
was significantly reduced in rats exposed peri-arterially with 
Cl-Ad (20 μmol/L in 25% pluronic gel). Bar graph compares the 
intimal area in rats receiving vehicle (n=7) versus Cl-Ad (n=7) 
after injury. Data are mean±SEM. B, Inhibitory effects of Cl-Ad 
on proliferation of vascular smooth muscle cells (VSMCs) in the 
intima 7 days after balloon injury. Image shows representative 
photomicrographs (40× magnification) of cross sections of 
carotid arteries stained for Ki67-positive proliferating VSMCs. 
Bar graph compares the number of Ki67-positive cells in placebo 
versus Cl-Ad–treated groups. Data are mean±SEM. C, Effects of 
Cl-Ad on neointimal expression of S-phase kinase–associated 
protein-2 (Skp2) and p27Kip1 proteins in vivo. Rats were treated 
with placebo (n=5) or Cl-Ad (20 μmol/L in 25% pluronic gel, n=5) 
and were euthanized on day 8. Carotid arteries were snap-frozen 
in liquid nitrogen. Subsequently, segments from placebo or 
Cl-Ad–treated animals were homogenized, lysed, and proteins 
analyzed using Western blotting. Bar graph depicts the changes 
in optical density (OD) of Skp2 or p27Kip1 normalized to β-actin. 
*P<0.05 vs placebo.
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A2B receptor stimulation of cAMP production and sequential 
activation of PKA. This concept is supported by a previous 
report that cAMP inhibits neointima formation via PKA acti-
vation and by downregulating Skp2 and upregulating p27Kip1 
in rat aortic VSMCs.38,39,51
Recent studies provide strong evidence for a major role 
of p27Kip1 upregulation in mediating anti-mitogenic actions in 
many cell types.38,51–53 Decreased or defective expression of 
p27Kip1 is linked to proliferative disorders, including athero-
sclerosis, restenosis after balloon injury, and cancer. In ani-
mal models, molecular approaches for targeted upregulation 
of p27Kip1 prevent injury-induced intimal thickening, as well 
as cancer cell growth.53 Our finding that 2-chloroadenosine 
induces p27Kip1 expression via A2B receptors suggests that 
p27Kip1 mediates in part the anti-mitogenic effects of A2B 
receptors. Consistent with this notion, our experiments show 
that the stimulatory effects of 2-chloroadenosine on p27Kip1 
expression and inhibitory effects on HCASMC proliferation 
are blocked by A2B receptor antagonism or knockdown of A2B 
receptors. Moreover, silencing of p27Kip1 in HCASMCs abro-
gates the inhibitory effects of 2-chloroadenosine on cell pro-
liferation and the stimulatory effects of 2-chloroadenosine on 
p27Kip1 expression. Similar to 2-chloroadenosine, the inhibi-
tory effects of MECA and cAMP are abrogated in HCASMCs 
with silenced p27Kip1, suggesting that p27Kip1 is a key media-
tor for the anti-mitogenic actions of 2-chloroadenosine, which 
requires the sequential involvement of A2B receptors and 
cAMP generation.
To confirm that the observed anti-mitogenic effects of ade-
nosine in HCASMCs in vitro would also translate to prevent-
ing vascular remodeling in vivo, we investigated the effects of 
2-chloroadenosine on injury-induced neointima formation. In 
this regard, we used the rat carotid artery injury model. The 
present study showed that treatment of rats peri-arterially with 
2-chloroadenosine significantly inhibited intimal thicken-
ing. Moreover, the inhibitory effects of 2-chloroadenosine on 
neointima formation were associated with downregulation of 
Skp2 and upregulation of p27Kip1. Taken together, these find-
ings suggest that 2-chloroadenosine prevents intimal thick-
ening in part by downregulating the expression of Skp2 and 
upregulating p27Kip1 levels. These findings are consistent with 
recent reports that injury-induced intimal thickening54,55 and 
high-lipid diet–induced atherosclerosis56 are increased in mice 
lacking A2B receptors, suggesting that the anti-vasoocclusive 
effects of adenosine are A2B receptor–mediated. Interestingly, 
in the present study, 2-chloroadenosine reduced neointimal 
area without altering lumen area. This suggests that 2-chloro-
adenosine blocked both neointimal formation and remodeling 
such that lumen area remained constant with a more normal 
intimal lining.
In mast cells57 and cardiac fibroblasts,58 A2B receptors 
couple to protein kinase C, and it is conceivable that this also 
occurs in HCASMCs. However, if so, this would probably not 
contribute to inhibition of HCASMC proliferation because 
our previous studies suggest that PKC is involved in stimulat-
ing, rather than inhibiting, VSMC proliferation.59
Our finding that application of 2-chloroadenosine peri-
arterially inhibits injury-induced intimal thickening has 
potential therapeutic significance. Restenosis after balloon 
angioplasty is a major post-angioplasty–associated clinical 
problem. Because abnormal growth of HCASMCs occurs 
mainly during the first 7 days after angioplasty47 and peri-arte-
rial application of 2-chloroadenosine inhibits intimal thicken-
ing, its peri-arterial application may prevent restenosis after 
balloon angioplasty in humans. Peri-arterial application may 
also resolve the limitations associated with the rapid clearance 
and short half-life of adenosine or its analogs.
Our data provide evidence that 2-chloroadenosine is 
effective in inhibiting HCASMC growth and injury-induced 
neointima formation. Likely, adenosine would mimic the 
Figure 11. A, Concentration (0, 0.01, 0.1, 1 μmol/L)–response 
relationships for the inhibition of DNA synthesis (3H-thymidine 
incorporation) by 2-chloroadenosine (Cl-Ad) and adenosine (Ad) 
in human coronary artery smooth muscle cells (HCASMCs). B, 
The effects of 100 nmol/L of 2-chloroadenosine (Cl-Ad) and 
adenosine (Ad) on cell number in the presence and absence 
of MRS1754 (MRS; selective A2B antagonist, 100 nmol/L) or 
inhibitory effects of adenosine in presence or absence of 
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; 1 μmol/L) plus 
5-iodotubercidin (IDO; 0.1 μmol/L) and with or without MRS1754 
(100nmol/L). C, The effects of adenosine on p27Kip1 and S-phase 
kinase–associated protein-2 (Skp2) expression in HCASMCs 
treated with or without adenosine (Ad; 100 nmol/L) for 48 hours. 
*P<0.05 vs no treatment; §P<0.05 significant reversal of inhibitory 
effects; #P<0.05 significant increase of inhibitory effects. Values 
represent mean±SEM from 3 separate experiments using 
separate HCASMCs, each conducted in triplicate. The optical 
density (OD) ratio in the bar graphs represents Skp2 or p27Kip1 to 
β-actin ratio.
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antiproliferative/anti-vasoocclusive effects of 2-chloro-
adenosine. Indeed, our findings that adenosine inhibits 
HCASMC growth, inhibits Skp2 expression, and induces 
p27Kip1 expression suggest that adenosine would also medi-
ate vascular protective actions. However, because of rapid 
catabolism of adenosine by adenosine kinase and adenos-
ine deaminase, adenosine likely would be less potent than 
2-choroadenosine. Although adenosine’s effect on neointima 
formation in vivo was not assessed in the present study, exper-
iments using A2B receptor knockout mice provide evidence 
for enhanced proliferation of VSMCs following endothelial 
denudation.53,54 This suggests that endogenous adenosine 
indeed is capable of suppressing intimal growth and vascular 
remodeling, which lead to vascular occlusion. Future stud-
ies using adenosine in pluronic acid gels are required to con-
firm whether adenosine has a physiological role in regulating 
growth of VSMCs.
Experiments by Shen et al60,61 demonstrate that A1 recep-
tors, rather than A2B receptors, are dominant in porcine cor-
onary artery smooth muscle cells and that, in this setting, 
adenosine stimulates proliferation via A1 receptor activation. 
Because A1 receptors inhibit, rather than stimulate, adenylyl 
cyclase, the findings of Shen et al are highly consistent with 
the mechanism proposed in Figure 1. Indeed we find that 
silencing of A2B receptors augments HCASMC proliferation 
via activation of A1 receptors by endogenous adenosine. Taken 
together, our finding and the findings of Shen et al suggest the 
possibility that the ratio of A1 to A2B receptors in HCASMCs 
in individual patients contributes significantly to the risk of 
coronary artery disease. If true, this would be an extremely 
important concept because this novel idea would suggest that 
administration of A1 receptor antagonists would be protective 
in patients with a high A1 to A2B ratio, whereas an A2B recep-
tor agonist would be preferred in patients with a high A2B to 
A1 ratio (ie, personalized medicine). However, a caveat is that 
A2B receptors when activated chronically can induce profi-
brotic and proinflammatory effects.62,63 Therefore, it may be 
important to limit the duration of treatment with A2B receptor 
agonists to just the critical time period in which HCASMC 
proliferation occurs in response to injury.
It is interesting that in the absence of A2B receptors, A1 
receptor activation leads to HCASMC proliferation. Given 
that A1 receptors have much higher affinity for adenosine, 
why would their effect not predominate? There are reports 
that A1 receptors form heterodimers with A2A receptors and 
β-adrenoceptors and that heterodimer formation blocks A1 
receptor signaling.62,63 Therefore, one possibility is that in 
HCASMCs, A2B receptors directly block A1 receptor signal-
ing via heterodimerization. Another possibility is that A2B/
Gs-mediated stimulation of adenylyl cyclase overrides A1/
Gi-mediated signaling, despite higher agonist binding to A1 
receptors.
In conclusion, we provide strong evidence that (1) ade-
nosine inhibits HCASMC proliferation and migration; (2) the 
inhibitory effects of adenosine on HCASMC proliferation are 
mediated via A2B receptor activation of adenylyl cyclase, lead-
ing to the accumulation of cAMP and stimulation of PKA; 
(3) PKA inhibits HCASMC proliferation by blocking multiple 
signaling pathways (ERK1/2, Akt, and Skp2) that converge 
at cyclin D—the net result being a reduced expression and 
function of this key G1 cyclin that governs cell-cycle progres-
sion; (4) this mechanism is operative in vivo; and (5) if the A2B 
receptor system is deficient, A1 receptors become dominant 
and increase HCASMC proliferation.
Perspectives
Activation of A2B receptors by adenosine inhibits HCASMC 
proliferation. This effect is profoundly efficacious because the 
A2B receptor/adenylyl cyclase/cAMP/PKA pathway blocks 
cell cycle progression by inhibiting multiple downstream sig-
naling events that are required for cyclin D production and 
function. Because A2B and A1 receptors have opposing effects 
on HCASMC proliferation, pharmacological activation of A2B 
receptors or inhibition of A1 receptors or both may prevent 
vascular remodeling associated with coronary artery disease, 
hypertension, atherosclerosis, and restenosis.
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What Is New?
•	Endogenous and exogenous adenosine inhibits human coronary artery 
smooth muscle cell (HCASMC) proliferation and migration.
•	The inhibitory effect of adenosine on HCASMC proliferation is mediated 
via A
2B
 receptor activation of adenylyl cyclase, leading to the accumula-
tion of cAMP and stimulation of protein kinase A.
•	Protein kinase A inhibits HCASMC proliferation by blocking multiple sig-
naling pathways (ERK1/2, Akt, and Skp2) that converge at cyclin D—the 
net result being a reduced expression and function of this key G1 cyclin 
that governs cell-cycle progression.
•	Adenosine analogues can be applied peri-arterially in a slow release gel 
formulation to inhibit vascular injury–induced neointimal hyperplasia.
•	 If the A2B receptor system becomes deficient, A1 receptor signaling be-
comes dominant and increases HCASMC proliferation.
What Is Relevant?
•	A2B receptor activation is a straightforward approach to inhibit HCASMC 
proliferation and migration.
•	 It is possible to apply A2B receptor agonists peri-arterially to block neo-
intimal hyperplasia while obviating unwanted systemic adverse effects.
•	The ratio of A1 to A2B receptor expression may determine risk of coronary 
artery disease and the response to adenosine receptor agonists.
•	Other agents that modulate the actions of ERK1/2, Akt, Skp2, p27Kip1, 
cyclin D, Rb, or cyclin A may have therapeutic efficacy in cardiovascular 
medicine.
Summary
The adenosine/A
2B
 receptor/cAMP/protein kinase A axis inhibits 
HCASMC proliferation by blocking multiple signaling pathways 
(ERK1/2, Akt, and Skp2) that converge at cyclin D; the net result 
being a reduced expression and function of this key G1 cyclin that 
governs cell-cycle progression.
Novelty and Significance
